Article Text

Download PDFPDF
Extended report
A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg–Strauss, EGPA): monocentric experiences in 150 patients
  1. Frank Moosig1,
  2. Jan Phillip Bremer1,
  3. Bernhard Hellmich2,
  4. Julia Ulrike Holle1,
  5. Konstanze Holl-Ulrich3,
  6. Martin Laudien4,
  7. Christine Matthis5,
  8. Claudia Metzler6,
  9. Bernhard Nölle7,
  10. Gert Richardt8,
  11. Wolfgang L Gross1
  1. 1Department of Rheumatology, University Hospital Schleswig-Holstein and Klinikum Bad Bramstedt, Bad Bramstedt, Germany
  2. 2Department of Internal Medicine, University of Tübingen and Hospital Plochingen, Plochingen, Germany
  3. 3Department of Pathology, University of Lübeck, Lübeck, Germany
  4. 4Department of Otorhinolaryngology, Head and Neck Surgery, University of Kiel, Kiel, Germany
  5. 5Department of Social Medicine, University of Lübeck, Lübeck, Germany
  6. 6Department of Internal Medicine, Hospital Barmherzige Brüder, Regensburg, Germany
  7. 7Department of Ophthalmology, University of Kiel, Kiel, Germany
  8. 8Department of Cardiology, Hospital Bad Segeberg, Bad Segeberg, Germany
  1. Correspondence to Dr Frank Moosig, Department of Rheumatology, University Hospital Schleswig-Holstein and Klinikum Bad Bramstedt, Oskar-Alexander-Street 26, Bad Bramstedt 24576, Germany, f.moosig{at}


Objective To evaluate a vasculitis centre based management strategy for eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA).

Methods A retrospective cohort study at a vasculitis referral centre was performed. All EGPA patients admitted from 1990 to 2009 were included. A structured interdisciplinary work-up for proof of diagnosis, Disease Extent Index and Birmingham Vasculitis Activity Score was performed. Immunosuppressive therapy was initiated and regularly adapted. Treatment targets were induction and maintenance of remission according to definitions given by the European League Against Rheumatism and the European Vasculitis Study Group. Outcomes were mortality, rate of remission, relapses, adverse events and prednisolone-dose.

Results Out of 269 patients with suspected EGPA 150 fulfilled the inclusion criteria. Of those, 104 had more than one follow-up visit resulting in a mean follow up of 53±4.9 months. By using additional data sources the follow-up concerning survival was extended to 92±5 month. Severe organ manifestations occurred at heart (46%), kidney (18%) and lungs (10%). Cyclophosphamide was used in 107 patients (71%). The prednisolone-doses of all patients were within the targeted range (i.e. ≤7.5mg) in 69% of the total follow-up time; the median dose at end of follow-up was 5mg/d. The 10-year survival rate was 89% resulting in mortality comparable to the general population (SMR 1.29). Only patients with cardiac failure associated with EGPA had an increased mortality (SMR 3.06).

Conclusions Regular re-evaluation and target-orientated adaption of therapy may lead to normalization of life expectancy and attenuation of disease progression. Continued centre based interdisciplinary treatment should be standard of care.

  • Systemic vasculitis
  • Outcomes research
  • Multidisciplinary team-care

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.